Allogene Therapeutics (ALLO) Accounts Payables (2018 - 2026)

Allogene Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 2.47% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (down 2.47% YoY), while the FY2025 annual figure was $4.3 million, down 20.84% from the prior year.
• Accounts Payables came in at $4.9 million for Q1 2026 at Allogene Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $14.7 million in Q1 2023 to a low of $3.7 million in Q3 2025.
• A 5-year average of $7.8 million and a median of $5.9 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 68.67% in 2023 and tumbled 62.5% in 2025, its largest moves.
• Allogene Therapeutics' Accounts Payables stood at $13.9 million in 2022, then slumped by 57.54% to $5.9 million in 2023, then dropped by 8.53% to $5.4 million in 2024, then slipped by 20.84% to $4.3 million in 2025, then climbed by 15.53% to $4.9 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.9 million, $4.3 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison